Urokinase induces its own expression in Beas2B lung epithelial cells.
The urokinase-type plasminogen activator (uPA) interacts with its receptor (uPAR) to promote local proteolysis as well as cellular proliferation and migration. These functions contribute to the pathogenesis of lung inflammation and remodeling as well as the growth and invasiveness of lung neoplasms. In this study, we sought to determine if uPA alters its own expression in lung epithelial cells. Using immunoprecipitation and Western and Northern blotting techniques, we found that uPA treatment enhanced uPA expression in Beas2B lung epithelial cells in a time- and concentration-dependent manner. The induction of uPA expression is mediated through its cell surface receptor uPAR and does not require uPA enzymatic activity. The amino-terminal fragment of uPA, lacking the catalytic domain, is sufficient to induce uPA expression. The serine protease plasmin and the protease inhibitor aprotinin failed to alter uPA-mediated uPA expression, whereas alpha-thrombin potentiated the response. Pretreatment of Beas2B cells with a tyrosine kinase inhibitor, herbimycin, suggests that activation of tyrosine kinase(s) is involved in the uPA-mediated uPA expression. Induction of uPA expression by exposure of lung-derived epithelial cells to uPA is a newly defined pathway by which this protease could influence expression of local fibrinolytic activity and other uPA-dependent cellular responses germane to lung inflammation or neoplasia.
Department of Medical Specialties, The University of Texas Health Center at Tyler, Tyler, Texas 75708, USA. sreerama.shetty@uthct.edu
Sreerama
S
Shetty
Usha R
UR
Pendurthi
Prathap Kumar Shetty
PK
Halady
Ali O
AO
Azghani
Steven
S
Idell
D007611:Aprotinin / Q000494:pharmacology; D016227:Benzoquinones; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D010450:Endopeptidases / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004847:Epithelial Cells / Q000187:drug effects / Q000201:enzymology; D006801:Humans; D047029:Lactams, Macrocyclic; D008168:Lung / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology*; D008970:Molecular Weight; D009994:Osmolar Concentration; D010446:Peptide Fragments / Q000494:pharmacology; D010744:Phosphoric Monoester Hydrolases / Q000037:antagonists & inhibitors; D010766:Phosphorylation; D011480:Protease Inhibitors / Q000494:pharmacology; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D011809:Quinones / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D011956:Receptors, Cell Surface / Q000502:physiology; D055293:Receptors, Urokinase Plasminogen Activator; D017828:Rifabutin / Q000031:analogs & derivatives; D013997:Time Factors; D015533:Transcriptional Activation; D014568:Urokinase-Type Plasminogen Activator / Q000737:chemistry / Q000235:genetics / Q000378:metabolism* / Q000494:pharmacology*
D016227:Benzoquinones; D004338:Drug Combinations; D004791:Enzyme Inhibitors; D047029:Lactams, Macrocyclic; C524898:PLAUR protein, human; D010446:Peptide Fragments; D011480:Protease Inhibitors; D011809:Quinones; D012333:RNA, Messenger; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; D017828:Rifabutin; C020754:herbimycin; D007611:Aprotinin; D011505:Protein-Tyrosine Kinases; D010744:Phosphoric Monoester Hydrolases; D010450:Endopeptidases; D014568:Urokinase-Type Plasminogen Activator